ELECTRA THERAPEUTICS INC ETRA

Gary S. Koe, Ph.D., has served as our Chief Technical Officer since May 2025. Previously, Dr. Koe served as our Senior Vice President, Head of Technical Operations from May 2024 to May 2025 and Vice President, Head of Technical Operations from November 2023 to May 2024. Dr. Koe was also Vice President, Technical Operations at Star Therapeutics from March 2022 to November 2023. Dr. Koe also served as Executive Director, Head of Operations at Star Therapeutics from November 2019 to March 2022. Prior to joining us, Dr. Koe served as Executive Director of Technical Operations at Aravive, Inc., a biotechnology company (Aravive), from 2015 to 2019. Dr. Koe earned a Ph.D. in chemical engineering from the University of California, Los Angeles, and his B.S. in chemical engineering from the University of California, Davis.

Graham Parry, Ph.D., has served as our Chief Scientific Officer since December 2023. Prior to joining us, Dr. Parry served as Executive Vice President, Translational Sciences at Star Therapeutics from January 2023 to December 2023, where he worked cross-functionally across the company's portfolio to advance treatments for multiple diseases. Prior to Star Therapeutics, Dr. Parry served as Senior Vice President, Translational Sciences at Third Harmonic Bio, Inc., a privately held clinical-stage biotechnology company, from August 2019 to December 2022. Dr. Parry earned a Ph.D. in biochemistry at the University of London and a B.Sc. in applied biology at Brunel University of London.

Kim-Hien Dao, D.O., Ph.D., has served as our Chief Medical Officer since May 2024 and previously served as our Vice President, Head of Clinical Development from April 2023 to May 2024. Prior to joining us, Dr. Dao served as Senior and Executive Medical Director of Clinical Development at Astex Pharmaceuticals, Inc., a privately held pharmaceutical company, from November 2019 to March 2023, where she worked on drug development programs for solid tumors and hematological malignancies. Dr. Dao earned her D.O. and Ph.D. in biochemistry and molecular biology from Michigan State University and trained in hematology-medical oncology at the University of California, San Diego.

Chris Clark, C.F.A., has served as our Chief Financial Officer since August 2026 and as our Executive Vice President, Strategy and Finance from December 2025 to August 2026. Previously, Mr. Clark served as Portfolio Manager, Equity Analyst - HealthCare at RS Investments, a Victory Capital investment franchise, a publicly held investment management company, from May 2007 to May 2025. Mr. Clark also served as a Research Associate at TIAA-CREF, a financial services organization, from 2004 to 2007, where he focused on global pharmaceuticals. Mr. Clark earned his B.A. in economics from the University of Virginia and is a chartered financial analyst.

Thomas Geninatti, Ph.D., has served as a member of our board of directors since October 2025. Dr. Geninatti has served as a Principal of Nextech Invest AG, a biotechnology investment firm (Nextech Invest), since October 2025 and as a Senior Associate from September 2024 to October 2025. Dr. Geninatti has served as a member of the board of directors of Hexagon Bio, Inc., a privately held biotechnology company, since January 2025. Prior to Nextech Invest, he served in numerous roles of increasing responsibility at Gilead from December 2019 to September 2024, most recently serving as Senior Director of Corporate Development. Dr. Geninatti took a brief hiatus from Gilead from May 2022 to September 2022 to serve as Senior Director, Business Development & Licensing, Oncology at Bayer AG. Prior to joining Gilead in December 2019, Dr. Geninatti served as a senior associate project manager and consultant for Deallus Consulting Limited, a global life science consulting firm. Dr. Geninatti earned a Ph.D. in bioengineering from a joint program between the University of the Chinese Academy of Sciences and the Houston Methodist Research Institute, as well as B.S. and M.S. degrees in Biomedical Engineering from Politecnico di Torino, Italy.

Quehuong (Kathy) Dong, Pharm.D., M.B.A., has served as our President and Chief Executive Officer and a member of our board of directors since October 2023. She has also served as President and Chief Executive Officer and a member of the board of managers of Electra Therapeutics LLC since October 2023. From April 2019 to October 2023, Dr. Dong served as Chief Operating Officer of Star Therapeutics, Inc., a privately held biotechnology company (Star Therapeutics), where she held strategic and operational responsibilities across the company's portfolio. Dr. Dong also served as Chief Operating Officer at Vega Therapeutics Inc., a privately held biotechnology company, from April 2019 to October 2023. Prior to Star Therapeutics, Dr. Dong served as Vice President of Commercial Development at True North Therapeutics, Inc., a privately held biotechnology company (True North). Following True North's acquisition by Bioverativ, Inc. (which was subsequently acquired by Sanofi S.A. (Sanofi)), Dr. Dong served as Head of New Product Planning for the complement franchise at Sanofi, a publicly held pharmaceutical company. Her tenure from True North through Sanofi was March 2017 to March 2019. Earlier in her career, Dr. Dong served as Director, HCV Marketing at Gilead Sciences, Inc., a publicly held biopharmaceutical company (Gilead). Dr. Dong has also served on the board of directors of Neuron23, Inc., a privately held precision neurology and immunology therapeutics company (Neuron23), since June 2022. Dr. Dong earned her Pharm.D. and M.B.A. at the University of New Mexico and completed a postdoctoral fellowship through Rutgers University.

Beth Seidenberg, M.D., has served as a member of our board of directors since March 2019. Dr. Seidenberg is the founding Managing Director of Westlake BioPartners, a life sciences venture capital firm, formed September 2018. Dr. Seidenberg is also a general partner at Kleiner Perkins Caufield and Byers, LLC, a venture capital firm, where she has primarily focused on life sciences investing since May 2005. From February 2002 to December 2004, Dr. Seidenberg served as the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, a publicly held biotechnology company. Prior to that, Dr. Seidenberg was a senior executive in research and development at Bristol-Myers Squibb, a publicly held biopharmaceutical company, and at Merck & Co., Inc., a publicly held biopharmaceutical company. Dr. Seidenberg has served on the board of directors of Latigo Biotherapeutics, Inc., a publicly held biopharmaceutical company, since July 2024, Vera Therapeutics, Inc., a publicly held biotechnology company, since June 2016, Kyverna Therapeutics, Inc., a publicly held biopharmaceutical company, since September 2018, Sagimet Biosciences Inc., a publicly held biotechnology company, since April 2007, and several other privately held life sciences companies. Dr. Seidenberg previously served on the board of directors of Acelyrin, Inc., a publicly held biopharmaceutical company, from October 2020 to May 2025, Atara Biotherapeutics, Inc., a publicly held biopharmaceutical company, from August 2012 to June 2023, and Progyny, Inc., a publicly held fertility benefit management company, from May 2010 to November 2024. Dr. Seidenberg earned her B.A. in Biology and Anthropology from Barnard College and her M.D. from the University of Miami School of Medicine and completed her post-graduate training at The Johns Hopkins University, George Washington University, and the National Institutes of Health.

Nancy Stagliano, Ph.D., has served as our Chairperson and member of our board of directors since March 2019. Dr. Stagliano has served as the chair of the board of directors of Neuron23 since October 2018 and as Chief Executive Officer of Neuron23 since October 2020. Dr. Stagliano has also served as chair of the board of directors of Star Therapeutics since June 2018. In addition, Dr. Stagliano has served as executive chair of Sundance Biosciences, Inc., a privately held biotechnology company, since January 2026. Dr. Stagliano previously served as Chief Executive Officer of True North until its acquisition by Bioverativ, Inc. in 2017. Prior to that, Dr. Stagliano served as Chief Executive Officer of iPierian, Inc., a privately held biotechnology company focused on neurodegenerative disease, from 2011 until its acquisition by Bristol-Myers Squibb Company (Bristol-Myers Squibb) in 2014. She also served as Chief Executive Officer of CytomX Therapeutics, Inc., a publicly held clinical-stage biopharmaceutical company, from 2008 to 2011. Dr. Stagliano earned her Ph.D. in neuroscience from the University of Miami School of Medicine and completed a postdoctoral fellowship at Harvard Medical School, as well as an M.S. in biomedical engineering and a B.S. in electrical engineering, both from Drexel University.

Matthew Fust, M.B.A., has served as a member of our board of directors since November 2023. Mr. Fust has served on the board of directors of Atara Biotherapeutics, Inc. since March 2014, Crinetics Pharmaceuticals, Inc. since March 2018, Ultragenyx Pharmaceutical, Inc. since January 2014, and Neumora Therapeutics, Inc. since December 2020, each of which are publicly held biotechnology companies. Mr. Fust was previously Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a publicly held biopharmaceutical company, from January 2009 through its acquisition by Amgen Inc. (Amgen) in October 2013. Mr. Fust continued as an employee of Amgen until January 2014. From May 2003 to December 2008, Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a publicly held specialty pharmaceutical company. Mr. Fust earned his M.B.A. from the Stanford Graduate School of Business and his B.A. in Accounting from the University of Minnesota Duluth.

Carl L. Gordon, Ph.D., C.F.A., has served as a member of our board of directors since March 2019. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm, where he has served since January 1998. Dr. Gordon has served on the board of directors of Compass Therapeutics Inc., a publicly held biopharmaceutical company, since September 2015, BlossomHill Therapeutics, Inc., a publicly held biopharmaceutical company, since February 2021, Scribe Therapeutics Inc., a publicly held biopharmaceutical company, since March 2021, Lomond Therapeutics Holdings, Inc., a privately held biotechnology company, since August 2024, and currently serves on the boards of directors of several other privately held companies. Dr. Gordon previously served on the boards of directors of several publicly held companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 until December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon earned a B.A. in chemistry from Harvard College, a Ph.D. in molecular biology from the Massachusetts Institute of Technology and was a Fellow at The Rockefeller University.